syngo.via for Oncology
The key questions in oncology are:
- What is the tumor’s status?
- Was the therapy effective?
- To which extent did the tumor respond to therapy?
Imaging is of key importance to truly assess the effect of a treatment, as early as possible. Intra-therapy imaging can be an effective tool to assess therapy response, even before a treatment phase is complete. The prognostic power of PET imaging helps in effective and efficient patient management, as changes in metabolic activity can be detected even before changes in size are visible.
syngo®.via2 provides powerful functionalities to assist you in the evaluation of the change of tumor status in cancer patients.
Oncology follow-up is all about comparing cancer at different points in time. syngo.via’s Automatic Case Preparation virtually reads your mind: It automatically gathers images from your archives and arranges them in the layout and order you prefer to read them.
Tumor follow-ups no longer require you to search for patients and images in data bases. Current and prior studies are displayed for you immediately in your preferred layout on up to two monitors, for a comprehensive and intuitive follow-up assessment.
Therapy response assessment: Know if the tumor is growing, stable, or shrinking
Accuracy and reproducibility are key factors in tumor assessment. Findings from prior exams are automatically propagated to follow-up, and results regarding tumor growth are instantly provided within the context-specific report. Auto measurements of RECIST 1.0, RECIST 1.1, WHO, and tumor volume through syngo.via in CT images, as well as SUV quantification on PET allow more objective measurements and a better reproducibility of results because inter-reader or intra-reader dependencies are eliminated. In addition, the tumor growth rates and tumor burden can be calculated automatically. In case additional image data from MRI or PET is available for your patient, you can easily drag and drop them into your oncology reading layout. These images will be registered automatically with the CT data sets and displayed on up to two monitors. The anatomic registration facilitates synchronized scrolling and 3D case navigation, regardless of the slice thickness. Last but not least,syngo.via with the syngo.mCT Oncology1 Engine Pro enables you to segment and quantify lesions in 3D on both PET and CT. Trending these parameters over time provides valuable information for therapy response assessment.
1Regulatory clearance with syngo.PET&CT Oncology.
2syngo.via can be used as a stand-alone device or together with a variety of syngo.via-based software options which are medical devices on their own rights.